Literature DB >> 35037949

miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis.

Chaonan Zhu1, Shuai Wang2, Maogen Zheng2, Zhiquan Chen2, Guochen Wang2, Jun Ma3, Bin Zhang1, Wuhao Huang1, Xiaoyan Sun1, Changli Wang4.   

Abstract

OBJECTIVE: To clarify the modulatory mechanism of miR-31-5p in lung adenocarcinoma (LUAD) progression in vivo and in vitro.
METHODS: The Cancer Genome Atlas (TCGA) database was employed to access LUAD-related miRNA and mRNA expression data. Downstream targets of miR-31-5p were predicted by public databases. The interaction between miR-31-5p and TNS1 was determined by dual-luciferase reporter assay. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to measure miR-31-5p and TNS1 expression levels in LUAD cells. Western blot was introduced to test protein expression levels of TNS1, p53, and apoptosis-related proteins. In-vitro functional assays were conducted to evaluate the biological effects of miR-31-5p on cell proliferation, colony formation, migration, and apoptosis. In-vivo tumor xenograft experiment was applied to examine the effects of miR-31-5p on LUAD tumor growth, followed by immunochemistry assays for assessing TNS1 and p53 expression levels in the tumor tissue.
RESULTS: miR-31-5p was prominently upregulated in LUAD tissue and was identified to present a similar trend in LUAD cell lines H1299, H23, and A549. miR-31-5p overexpression exerted an active role in cell proliferation and migration, but it suppressed cell apoptosis. Additionally, a reverse correlation between miR-31-5p and TNS1 regarding the expression level was identified, and TNS1 was verified to be a direct target of miR-31-5p. Besides, it was further validated by the rescue experiments that the tumor-promoting effects of miR-31-5p on LUAD cell functions were attenuated by TNS1 overexpression to some extent. The results based on the tumor xenograft experiment revealed that LUAD cell growth could be facilitated by miR-31-5p via the TNS1/p53 axis.
CONCLUSION: miR-31-5p facilitates LUAD cell progression mediated by the TNS1/p53 axis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Apoptosis; Lung cancer; Migration; Proliferation; miRNA

Mesh:

Substances:

Year:  2022        PMID: 35037949     DOI: 10.1007/s00066-021-01895-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  25 in total

1.  MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB.

Authors:  Hong Peng; Longfei Wang; Qiang Su; Kun Yi; Jingwei Du; Ziwei Wang
Journal:  Biomed Pharmacother       Date:  2018-11-02       Impact factor: 6.529

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 3.  Epithelial-mesenchymal transition and microRNAs: Challenges and future perspectives in oral cancer.

Authors:  Cátia Sofia da Costa Domingues; Beatriz Prazeres Serambeque; Mafalda Sofia Laranjo Cândido; Carlos Miguel Machado Marto; Francisco José de Baptista Veiga; Ana Bela Sarmento Antunes Cruz Ribeiro; Ana Rita Ramalho Figueiras; Maria Filomena Roque Botelho; Marília de Assunção Rodrigues Ferreira Dourado
Journal:  Head Neck       Date:  2018-08-18       Impact factor: 3.147

4.  Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial-Mesenchymal Transition.

Authors:  Bo Pang; Nan Wu; Rongwei Guan; Lin Pang; Xinlei Li; Su Li; Liudi Tang; Ying Guo; Jialei Chen; Donglin Sun; Haiming Sun; Jialin Dai; Jing Bai; Guohua Ji; Peng Liu; An Liu; Qiushi Wang; Sheng Xiao; Songbin Fu; Yan Jin
Journal:  Clin Cancer Res       Date:  2017-06-12       Impact factor: 12.531

5.  Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma.

Authors:  Jinlan He; Jianxiong He; Li Min; Yan He; Hui Guan; Jingjing Wang; Xingchen Peng
Journal:  Int J Cancer       Date:  2019-07-16       Impact factor: 7.396

6.  Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.

Authors:  A Carrato; A Vergnenègre; M Thomas; K McBride; J Medina; G Cruciani
Journal:  Curr Med Res Opin       Date:  2013-11-18       Impact factor: 2.580

7.  Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients.

Authors:  Isolde Summerer; Maximilian Niyazi; Kristian Unger; Adriana Pitea; Verena Zangen; Julia Hess; Michael J Atkinson; Claus Belka; Simone Moertl; Horst Zitzelsberger
Journal:  Radiat Oncol       Date:  2013-12-28       Impact factor: 3.481

Review 8.  Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer.

Authors:  Hong Zheng; Jia-Yu Liu; Feng-Ju Song; Ke-Xin Chen
Journal:  Cancer Biol Med       Date:  2013-09       Impact factor: 4.248

9.  miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer.

Authors:  Zhiyuan Lu; Qianting He; Jianfeng Liang; Wuguo Li; Qiao Su; Zujian Chen; Quan Wan; Xiaofeng Zhou; Laurel Cao; Jingjing Sun; Yu Wu; Lin Liu; Xinming Wu; Jinsong Hou; Keqian Lian; Anxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-11       Impact factor: 8.886

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  2 in total

1.  Downregulation of hsa-miR-30b-3p Inhibits the Oncogenicity of Lung Adenocarcinoma by Targeting the METTL7B Gene.

Authors:  Ning Li; Rui Li; Bin Song; Hong Ge; Yiqing Qu
Journal:  J Oncol       Date:  2022-05-20       Impact factor: 4.501

2.  A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.

Authors:  Weili Mao; Jiajing Zhou; Jie Hu; Kui Zhao; Zhenling Fu; Jun Wang; Kaili Mao
Journal:  Front Public Health       Date:  2022-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.